about
Is there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Biologics in asthma--the next step toward personalized treatmentA molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease.Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-SynucleinopathyA virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton ratsMast cells in airway diseases and interstitial lung diseaseTargeting IL4/IL4R for the treatment of epithelial cancer metastasis.Different Bla-g T cell antigens dominate responses in asthma versus rhinitis subjectsDevelopment of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival.Regulation of IL-4 receptor signaling by STUB1 in lung inflammation.Histamine stimulates hydrogen peroxide production by bronchial epithelial cells via histamine H1 receptor and dual oxidase.Asthma phenotyping, therapy, and prevention: what can we learn from systems biology?Cytokine profiles in allergic rhinitis.Epithelial function and dysfunction in asthma.Defining phenotypes in asthma: a step towards personalized medicine.Dupilumab: a novel treatment for asthma.Interleukin-4 -589C/T Polymorphism is Associated with Increased Pediatric Asthma Risk: A Meta-Analysis.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.Targeting key proximal drivers of type 2 inflammation in disease.Targeted Therapy for Severe Asthma: Identifying the Right Patients.Commonality of the IL-4/IL-13 pathway in atopic diseases.New treatment directions for IPF: current status of ongoing and upcoming clinical trials.Spectrum of T-lymphocyte activities regulating allergic lung inflammation.The development of allergic inflammation in a murine house dust mite asthma model is suppressed by synbiotic mixtures of non-digestible oligosaccharides and Bifidobacterium breve M-16V.Tumor-related interleukins: old validated targets for new anti-cancer drug development.Commentary: IL-4 and IL-13 receptors and signalingA detailed phenotypic analysis of immune cell populations in the bronchoalveolar lavage fluid of atopic asthmatics after segmental allergen challenge.Cytokines in chronic respiratory diseases.Dupilumab in the management of moderate-to-severe asthma: the data so far.Potassium currents inhibition by gambierol analogs prevents human T lymphocyte activation.Innate immunity in paediatric viral wheezers is virus specific and not interferon dependent.Investigational drugs for idiopathic pulmonary fibrosis.IL-4 driven transcription factor FoxQ1 is expressed by monocytes in atopic dermatitis and stimulates monocyte migration.New approaches for identifying and testing potential new anti-asthma agents.Dupilumab for the treatment of asthma.Allergic Rhinitis and Its Relationship with IL-10, IL-17, TGF-β, IFN-γ, IL 22, and IL-35.
P2860
Q26998459-1255D782-CA07-4923-9A95-FF6461ED6852Q28085614-7D5F7540-1C50-45FE-8E85-8B147A4483CBQ30406072-B35CFE12-D206-4244-889D-03E97298E65BQ35019131-DD1C9D47-836B-4B90-A344-3E9AA0BC392AQ36251566-049CA6CF-2735-4D8A-9981-6F3C9DC6B090Q36260500-8F563030-010A-41B1-B6E8-60FF89D21E5FQ36296416-BF3B38AF-FD96-4A69-963F-43529096AF78Q36303549-F591E49F-60C9-4753-9AFD-F006D9F10A69Q37168393-6C40989D-6394-44C9-B793-6D789DD73D2CQ37245208-C877B5AA-2049-42B5-B245-2672CAD33BB9Q37572504-ABCB2D35-50A9-4337-AF8D-1EE3E210977CQ37596112-395BDD3F-1EFD-433C-AE13-94EAEA4781A5Q38073596-801F28CE-AA39-42EF-B6F8-1F8077C26537Q38196334-9F44EC53-5B79-48A3-A357-3E5E92BDBE20Q38198788-FACBE90D-036E-49EB-9CC2-759478EAF9E2Q38209438-96B6AAA7-8E19-48B1-9245-FF58B08B2804Q38248590-064D590C-F483-40C3-BFB7-732EC215B8E0Q38393011-75C5FA03-DF85-4215-9B22-CA874589B04EQ38406177-BB84EC7B-28C3-4B30-A433-ED63EF8FB367Q38528048-0AA6FF77-DDDE-4517-AB92-2FA752089E80Q38608260-459AE803-41BD-47B6-8661-A02EC370E4A9Q39065311-EAC3EDCC-BE1D-46BA-83FF-4527CD53CB22Q39170851-3E4D9A34-C5BD-4838-882A-8A03C58938BEQ39330304-73FF773B-0919-4F20-88BB-E6609DD265E6Q39402895-103C18B6-E10D-4FCB-8D92-E4B0C7A0228BQ39846853-9FDF17E6-31E4-4648-BC5C-656F229D8590Q41716360-25ED39D6-D112-4486-B7A5-E56D2F7B6093Q41818218-BD0F3FC2-2CC9-4A69-AA09-8A295B634A01Q42006923-F834F752-A266-49F6-8C19-C0200F6F0E50Q42113962-57FC65B0-28C4-442C-B2FA-A0CBAC91B394Q42229455-D399F4F9-0E44-4273-BC21-33B318C81E91Q42704379-F3DA14CD-10F1-419E-A63F-C02CAA499739Q45346677-8B07EF96-99B1-4C9F-9C14-50CC9FB5E56FQ46325791-72DA07C6-1109-4DDE-9975-5E8431FDAB90Q47116025-C8440205-8E56-4BFE-B087-438E986C9961Q47873103-82E41ED5-70F3-4D2F-A006-2F5F7B7D555FQ49486790-D32FD6B3-A907-40D6-8A2F-A99BA2DCEB3EQ52564581-AD9946CC-3A3A-41BD-855D-CB473FEA88FE
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting interleukin-4 in asthma: lost in translation?
@ast
Targeting interleukin-4 in asthma: lost in translation?
@en
Targeting interleukin-4 in asthma: lost in translation?
@nl
type
label
Targeting interleukin-4 in asthma: lost in translation?
@ast
Targeting interleukin-4 in asthma: lost in translation?
@en
Targeting interleukin-4 in asthma: lost in translation?
@nl
prefLabel
Targeting interleukin-4 in asthma: lost in translation?
@ast
Targeting interleukin-4 in asthma: lost in translation?
@en
Targeting interleukin-4 in asthma: lost in translation?
@nl
P2860
P356
P1476
Targeting interleukin-4 in asthma: lost in translation?
@en
P2093
Guy F Joos
Guy G Brusselle
P2860
P304
P356
10.1165/RCMB.2012-0080TR
P50
P577
2012-04-26T00:00:00Z